GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of various products, services, and complementary digital solutions utilized in the diagnosis, treatment, and monitoring of patients across numerous global markets, including the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong. The company operates through four distinct segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment specializes in molecular imaging, computed tomography (CT), magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, along with women’s health products. In the Ultrasound segment, the company offers solutions for screening, diagnosis, treatment, and monitoring of specific diseases across various fields such as radiology, primary care, women’s health, cardiovascular care, and point-of-care diagnostics, as well as handheld ultrasound and surgical visualization tools. The Patient Care Solutions segment provides medical devices, consumable products, services, and digital solutions across patient monitoring, anesthesia delivery, respiratory care, diagnostic cardiology, and maternal-infant care. In Pharmaceutical Diagnostics, the firm supplies diagnostic agents including those used in CT, angiography, X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound for the radiology and nuclear medicine sectors. Additionally, this segment offers contrast media pharmaceuticals to enhance the visibility of tissues during imaging exams and molecular imaging agents, or radiopharmaceuticals, for diagnostic purposes. The earnings per share (EPS) is reported at $3.68 indicating the company's profitability on a per-share basis. The company's stock is identified with the symbol '$GEHC' in the market. The company recorded an operating income of $2,762,000,000.00 reflecting its earnings from core operations, while the cost of revenue stands at $12,378,000,000.00 showcasing its production and operational expenses. Moreover, the company reported a substantial revenue of $20,625,000,000.00 reflecting its strong market presence. The stock is reasonably priced at $74.91 appealing to a broad range of investors, and it has a high average trading volume of 3,610,730.00 indicating strong liquidity. With a mid-range market capitalization of $36,614,936,281.00 the company is recognized as a steady performer. It is a key player in the Medical - Healthcare Information Services industry, contributing significantly to the overall market landscape, and it belongs to the Healthcare sector, driving innovation and growth.